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Aims Ischaemia–reperfusion (IR) injury causes endothelium-dependent vasomotor dysfunction that can be prevented
by ischaemic preconditioning. The effects of IR injury and preconditioning on endothelium-dependent tissue plasmi-
nogen activator (t-PA) release, an important mediator of endogenous fibrinolysis, remain unknown.
Methods
and results
Ischaemia–reperfusion injury (limb occlusion at 200 mmHg for 20 min) was induced in 22 healthy subjects. In 12 sub-
jects, IR injury was preceded by local or remote ischaemic preconditioning (three 5 min episodes of ipsilateral or
contralateral limb occlusion, respectively) or sham in a randomized, cross-over trial. Forearm blood flow (FBF)
and endothelial t-PA release were assessed using venous occlusion plethysmography and venous blood sampling
during intra-arterial infusion of acetylcholine (5–20 mg/min) or substance P (2–8 pmol/min). Acetylcholine and
substance P caused dose-dependent increases in FBF (P, 0.05 for all). Substance P caused a dose-dependent
increase in t-PA release (P, 0.05 for all). Acetylcholine and substance P-mediated vasodilatation and substance
P-mediated t-PA release were impaired following IR injury (P, 0.05 for all). Neither local nor remote ischaemic pre-
conditioning protected against the impairment of substance P-mediated vasodilatation or t-PA release.
Conclusion Ischaemia–reperfusion injury induced substance P-mediated, endothelium-dependent vasomotor and fibrinolytic dys-
function in man that could not be prevented by ischaemic preconditioning.
Clinical Trial Registration Information: Reference number: NCT00789243, URL: http://clinicaltrials.gov/ct2/show/
NCT00789243?term=NCT00789243&rank=1
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Introduction
Acute arterial occlusion can lead to end-organ ischaemia and, ulti-
mately, infarction. Although treatment is usually directed at prompt
restoration of flow in the occluded artery, reperfusion itself may
trigger additional injury beyond that induced by ischaemia alone,
although the mechanism is poorly understood. Impaired
endothelium-dependent vasomotor function following ischaemia
and reperfusion has been demonstrated in experimental models1
and in vivo in man,2 and can be prevented by prior exposure to
intermittent sublethal ischaemia—ischaemic preconditioning—
induced either locally in the vascular bed immediately downstream
of the preconditioning stimulus, or remotely in an organ anatomi-
cally distant from the preconditioning stimulus.2,3 The effects of
ischaemia–reperfusion (IR) injury and ischaemic preconditioning
on other important aspects of endothelial function remain
unknown.
In addition to the regulation of vascular tone, the endothelium
is intimately involved in the prevention of intravascular thrombo-
sis through the endogenous fibrinolytic pathway.4 The activation
of plasminogen is a critical step in endogenous fibrinolysis, with
tissue plasminogen activator (t-PA) being the main plasminogen
activator in man. However, only a relatively small proportion
of the t-PA present in plasma is functionally active, largely due
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to binding and inhibition by the serpin, plasminogen activator
inhibitor type 1 (PAI-1). In plasma, PAI-1 is present in molar
excess over t-PA, hence for active unbound t-PA to reach a
thrombus, rapid local release is vital, fibrinolysis being much
more effective if t-PA is incorporated during, rather than after,
thrombus formation. Thus, the ability of the endothelium to
release t-PA rapidly plays a key role in determining local
endogenous fibrinolytic activity, with a reduction in local endo-
thelial t-PA release favouring thrombus formation and propa-
gation and, ultimately, vascular obstruction.5
Using forearm venous occlusion plethysmography and the
endothelium-dependent agonist, substance P, we have demon-
strated that substance P-induced t-PA release is impaired in
the forearm circulations of smokers6 and in patients with coron-
ary artery disease—the degree of impairment of t-PA release
correlating with the risk of future cardiovascular events.7 Simi-
larly, endothelial t-PA release is impaired in the coronary circu-
lation of patients with atherosclerotic coronary disease, the
extent of impairment being inversely proportional to plaque
burden.8
Preclinical models report an increase in local t-PA concen-
trations immediately following IR injury, which return to basal
levels within 10 min although these findings may be confounded
by intravascular pooling of t-PA.9– 13 In man, the acute effects of
IR injury on endogenous fibrinolysis are less clear. Plasma t-PA
concentrations are increased in patients with critical limb ischae-
mia,14 but reduced in patients with intermittent claudication.15
We hypothesized that, in keeping with endothelium-dependent
vasodilatation to acetylcholine, IR injury would impair endothelium-
dependent endogenous fibrinolysis and that ischaemic precondi-
tioning would protect against this. To address this, we
examined the effect of IR injury and ischaemic preconditioning
on substance P-mediated vasodilatation and t-PA release in vivo
in man.
Methods
The study was carried out in accordance with the Declaration of Hel-
sinki (2000) of the World Medical Association. The Lothian Research
Ethics Committee approved the study and all subjects gave written
informed consent.
Subjects
Twenty-two healthy male volunteers were recruited. All subjects
were non-smoking, taking no regular medications and clinically
well. Subjects abstained from vasoactive drugs for 7 days, caffeine-
containing drinks and alcohol for 24 h, and fasted for at least 4 h
before each visit. Subjects attended either for one study visit (Proto-
col 1) or for three study visits (Protocol 2), with at least 2 weeks
between each visit.
Study protocols
Protocol 1
Ischaemia–reperfusion injury was induced by cuff inflation around the
non-dominant upper arm to 200 mmHg for 20 min in 10 healthy sub-
jects (Protocol 1, Figure 1A). Forearm blood flow (FBF) responses to
intra-arterial acetylcholine (5–20 mg/min) were assessed at baseline
and at 15 and 45 min after IR injury.
Figure 1 Study protocols.
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Protocol 2
Local or remote ischaemic preconditioning, or sham, was performed
prior to the induction of IR injury in the non-dominant arm in 12 sub-
jects in a randomized, blinded, cross-over fashion (Protocol 2,
Figure 1B). Local or remote ischaemic preconditioning was induced
by cuff inflation around the non-dominant or dominant upper arm,
respectively, to 200 mmHg for 5 min on three occasions 5 min apart.
During sham procedures, the upper arm cuff was inflated to
10 mmHg for a similar time period. Forearm blood flow and plasma
concentrations of t-PA and PAI-1 antigen and activity during
intra-arterial infusion of substance P (2–8 pmol/min) were assessed
at baseline and 15 min after IR injury.
Intra-arterial drug administration
All studies were performed with patients lying supine in a quiet,
temperature-controlled (22–258C) room. Under local anaesthesia, a
27-gauge needle (Cooper Needle Works Ltd) was inserted into the
brachial artery of the non-dominant arm. The rate of intra-arterial
drug infusion remained constant throughout at 1 mL/min.
Forearm blood flow and blood pressure
Bilateral arterial FBF was measured using venous occlusion plethysmo-
graphy (Hokanson EC6 plethysmograph, DE Hokanson, Inc., USA, and
Chart v5.0.1 software, ADInstruments Ltd, UK) as previously
described.16 Plethysmographic data were extracted from the Chart
data files, and FBF calculated for individual venous occlusion cuff
inflations. Usually, the last five flow recordings in each 3 min measure-
ment period were calculated and averaged for each arm. Heart rate
and blood pressure were recorded in the non-infused arm at intervals
throughout the study using a semi-automated non-invasive oscillometric
sphygmomanometer (Takeda UA 751; Takeda Medical, Inc., Japan).
Venous blood samples and assays
For Protocol 2, 17-gauge venous cannulae were inserted bilaterally
into a large antecubital vein. Ten millilitres of blood was withdrawn
simultaneously from each arm at baseline and in the last minute of
each drug infusion period and collected into acidified, buffered
citrate (Biopool Stabilyte, Umea˚) for t-PA assays and citrate (Monov-
ette, Sarstedt, Numbrecht) for PAI-1 assays. Estimated net release of
t-PA antigen and activity were defined previously as the product of
the infused forearm plasma flow (based on the mean haematocrit
and the infused FBF) and the concentration difference between the
infused and non-infused arms.16 Samples were kept on ice before
being centrifuged at 2000g for 30 min at 48C. Platelet-free supernatant
was decanted and stored at 2808C before assay. Plasma t-PA (t-PA
Combi Actibind Elisa Kit, Technoclone, Vienna, Austria) and PAI-1
antigen and activity (Elitest PAI-1, Hyphen Biomed, Neuville-Sur-Oise,
France) concentrations were determined using enzyme-linked immu-
nosorbent assays.
Data analysis and statistics
The software package GraphPad PRISM 5 was used for analysis
(GraphPad Software, Inc., La Jolla, CA 92037, USA). All data are
expressed as mean+ SEM unless otherwise stated. Data were ana-
lysed using repeated measures two-way ANOVA, one-way ANOVA,
and paired Student’s t-test, where appropriate. Statistical significance
was defined as a two-sided P-value ,0.05.
Results
There were no differences in the heart rate, blood pressure, hae-
matocrit, FBF, or t-PA release at baseline between or during visits
(Table 1; Supplementary material online, Table S1 and Figure S1).
Ischaemia–reperfusion injury and ischaemic preconditioning were
well tolerated by all subjects, with no reported side effects.
Vasomotor function
Intra-arterial infusion of acetylcholine caused a dose-dependent
increase in the FBF in the infused arm in all studies (P, 0.05 for
all) that was attenuated by IR injury (P ¼ 0.007; Figure 2).
Substance P caused a dose-dependent increase in FBF in the
infused arm in all studies (P, 0.05 for all) that was impaired fol-
lowing IR injury (P, 0.01 for all; Table 2, Figure 3). Compared
with sham, neither local nor remote ischaemic preconditioning
altered the reduction in substance P-mediated vasodilatation fol-
lowing IR injury (Table 2, Figure 3).
Fibrinolytic function
Substance P caused a dose-dependent increase in absolute t-PA
antigen (P, 0.0005 for all; Table 3) and activity (P, 0.0001 for
all; Table 3), and net release of t-PA antigen and activity in the
infused arm in all studies (P, 0.01 for all; Figure 4) that was atte-
nuated by IR injury (P, 0.05 for all; Figure 4). Compared with
sham, neither local nor remote ischaemic preconditioning altered
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Table 1 Baseline characteristics
Parameter Protocol 1 Protocol 2*
IR injury Sham1 IR Local IPC1 IR Remote IPC1 IR
Age, years 23.6+1 22.3+1 22.3+1 22.3+1
Body mass index, kg/m2 23.8+1 23.5+0.5 23.5+0.5 23.5+ 0.5
Heart rate, b.p.m. 58.0+3 62.7+2 61.0+2 64.8+2
Mean arterial pressure, mmHg 92.4+2 96.5+2 96.3+2 93.5+3
Baseline haematocrit, % 43.6+1 41.6+1 41.7+1 39.8+2
IR, ischaemia–reperfusion injury; IPC, ischaemic preconditioning.
*P. 0.05 for all, paired Student’s t-test; sham + IR vs. local IPC + IR and sham + IR vs. remote IPC + IR.
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substance P-mediated release of t-PA antigen or activity following
IR injury (Table 3, Figure 4).
There were no differences in plasma PAI-1 concentrations at
baseline or following IR injury (Supplementary material online,
online data table).
Discussion
To our knowledge, this is the first study to examine the effect of IR
injury and ischaemic preconditioning on endogenous fibrinolysis in
man. Having first confirmed the validity of the forearm model using
acetylcholine, we have demonstrated that substance P-induced
vasodilatation and endothelial t-PA release are impaired following
IR injury. Neither local nor remote ischaemic preconditioning pro-
tected against the impairment of substance P-mediated vasodilata-
tion or t-PA release induced by IR injury.
A major finding of this study is that IR injury attenuates the
dynamic release of t-PA from the endothelium in the human per-
ipheral vasculature in vivo in man. Preclinical data, predominantly
from ex vivo models, suggest that short periods of IR injury are
associated with increased local t-PA concentrations immediately
after the onset of reperfusion.9– 13 In these experimental studies,
t-PA concentrations peaked 2–5 min after the onset of reperfu-
sion and returned to baseline within 10 min of reperfusion.
However, the capacity of the endothelium to release t-PA
appeared to decline with repeated episodes of vascular occlu-
sion.11 The apparent conflict between preclinical data and the
current study may be explained, at least in part, by temporal differ-
ences in the assessment of t-PA release relative to the onset of
reperfusion. We assessed the potential for t-PA release 15 min
after the ischaemic insult because we wished to avoid the potential
confounding of pooling of t-PA and the effects of the direct ischae-
mic stimulus itself. These effects underlie the principles of why
t-PA concentrations rise during the venous occlusion test.4
In contrast to the effects of ischaemic preconditioning on
acetylcholine-induced vasodilatation, we found no effect of ischae-
mic preconditioning on substance P-induced vasodilatation or
endothelial t-PA release following IR injury. The reason for these
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Table 2 Effect of ischaemia–reperfusion injury alone or ischaemia–reperfusion injury preceded by local or remote
ischaemic preconditioning on substance P-mediated vasodilatation in the infused and non-infused arms
Parameter Baseline Post-IR
Baseline Substance P (pmol/min) Baseline Substance P (pmol/min)
2 4 8 2 4 8
Sham-IPC + IR
FBF, mL/100 mL/min
Infused 1.8+0.2 6.2+0.6 7.3+0.7 8.9+0.8*, ** 1.9+0.2 4.7+0.7 5.3+0.8 6.6+0.9*, **
Non-infused 1.7+0.2 1.7+0.2 1.7+0.2 1.9+0.2 1.7+0.3 1.8+0.4 1.8+0.5 1.8+0.4
Local IPC + IR
FBF, mL/100 mL/min
Infused 2.3+0.3 6.2+0.5 7.7+0.6 9.7+0.8*, *** 2.2+0.3 5.0+0.7 5.9+0.8 7.2+1.0*, ***
Non-infused 2.0+0.2 2.0+0.2 1.9+0.2 2.2+0.3 2.0+0.3 1.9+0.2 1.9+0.3 2.0+0.3
Remote IPC + IR
FBF, mL/100 mL/min
Infused 2.4+0.4 6.4+0.6 7.8+1.0 10.1+1.3*, **** 2.3+0.3 5.4+0.5 6.4+0.6 7.8+0.9*, ****
Non-infused 2.0+0.3 1.8+0.3 1.8+0.3 1.9+0.3 1.8+0.3 1.8+0.3 1.7+0.2 1.8+0.3
FBF, forearm blood flow; IPC, ischaemic preconditioning; IR, ischaemia–reperfusion injury.
ANOVA dose response *P, 0.0001 for all; ANOVA baseline vs. post-IR **P, 0.0001, ***P ¼ 0.012, ****P ¼ 0.014.
Figure 2 Effect of ischaemia–reperfusion injury on
acetylcholine-mediated vasodilatation. IR indicates ischaemia–
reperfusion (Protocol 1). Data analysed using two-way ANOVA
with repeated measures.
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apparent differences is unclear but is likely to reflect differences in
intracellular signalling. Previous work has implicated the mitochon-
drial ATP-sensitive potassium channel in the protection of
acetylcholine-mediated vasodilatation afforded by ischaemic pre-
conditioning.17,18 In contrast, thrombin-stimulated release of t-PA
from endothelial cells appears to occur independently of both
Figure 3 Effect of ischaemia–reperfusion injury alone and ischaemia–reperfusion injury preceded by local or remote ischaemic precondition-
ing on substance P-induced vasodilatation (Protocol 2). IR indicates ischaemia–reperfusion; IPC, local ischaemic preconditioning; and RIPC,
remote ischaemic preconditioning. Data analysed using two-way ANOVA with repeated measures.
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Table 3 Effect of ischaemia–reperfusion injury alone or ischaemia–reperfusion injury preceded by local or remote
ischaemic preconditioning on substance P-mediated tissue plasminogen activator antigen and activity in the infused and
non-infused arms
Parameter Baseline Post-IR
Baseline Substance P (pmol/min) Baseline Substance (P pmol/min)
2 4 8 2 4 8
Sham-IPC + IR
t-PA antigen, ng/mL
Infused 3.2+0.7 3.8+0.7 3.8+0.6 5.2+0.7* 2.9+0.7 3.0+0.6 3.4+0.7 4.7+0.8*
Non-infused 3.0+0.7 3.3+0.7 3.6+0.7 3.4+0.6 2.8+0.6 3.2+0.6 3.3+0.7 3.1+0.6
t-PA activity, U/mL
Infused 0.6+0.1 0.9+0.1 1.1+0.2 1.7+0.3* 0.6+0.05 0.8+0.1 1.1+0.1 1.5+0.3*
Non-infused 0.4+0.1 0.4+0.1 0.4+0.1 0.6+0.1 0.6+0.1 0.7+0.05 0.6+0.05 0.6+0.05
Local IPC + IR
t-PA antigen, ng/mL
Infused 3.1+0.6 3.4+0.7 3.8+0.8 4.8+1.1* 3.0+0.7 3.2+0.7 3.6+0.9 4.7+1.4**
Non-infused 3.1+0.6 3.1+ 0.6 3.2+0.7 3.2+0.6 2.9+0.6 3.0+0.6 3.2+0.6 3.0+0.6
t-PA activity, U/mL
Infused 0.5+0.1 0.7+0.1 1.0+0.1 1.4+0.2* 0.6+0.1 0.8+0.1 1.1+0.2 1.4+0.2*
Non-infused 0.5+0.1 0.5+0.1 0.4+0.1 0.6+0.1 0.6+0.05 0.6+0.05 0.6+0.05 0.7+0.05
Remote IPC + IR
t-PA antigen, ng/mL
Infused 3.5+0.6 3.9+0.6 4.5+0.9 6.2+1.2* 3.0+0.6 3.3+0.7 3.6+0.6 4.3+0.9**
Non-infused 3.2+0.6 3.3+0.6 3.9+0.7 3.4+0.6 3.3+0.7 3.0+0.6 3.1+0.7 3.2+0.6
t-PA activity, U/mL
Infused 0.6+0.1 0.8+0.1 1.2+0.2 1.8+0.3* 0.6+0.1 0.7+0.1 1.0+ 0.2 1.1+0.3*
Non-infused 0.4+0.1 0.5+0.1 0.5+0.1 0.3+0.1 0.5+0.1 0.5+0.1 0.4+0.1 0.6+0.1
t-PA, tissue-plasminogen activator; IPC, ischaemic preconditioning; IR, ischaemia–reperfusion injury.
ANOVA dose response *P, 0.0001 for all, **P ¼ 0.0004.
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nitric oxide and K+ channels in vitro,19 and if anything, in contrast to
acetylcholine-mediated vasodilatation, nitric oxide inhibition aug-
ments thrombin-induced t-PA release in vivo in man.20
Limited preclinical data have suggested a potential role for sub-
stance P in the mechanism of ischaemic preconditioning.21 We
have previously demonstrated that forearm vascular responses to
substance P are highly reproducible at 30 min and 7 days.22
Taken together, our results do not support the hypothesis that
substance P-induced signalling protects against endothelial dysfunc-
tion induced by IR injury, although we acknowledge that the
current study was not designed to specifically address this issue.
Clinical relevance
Our findings have potentially significant clinical implications.
Despite optimal antithrombotic therapy, early arterial reocclusion
and microvascular obstruction remain recognized complications
following reperfusion therapy for acute myocardial infarction and
are associated with adverse clinical outcomes.23 –26 A number of
mechanisms have been implicated in the pathophysiology of micro-
vascular obstruction, or ‘no reflow’, including vasomotor dysfunc-
tion and vasospasm, localized oedema and inflammation,27
coronary micro-embolization,28 and in situ thrombus for-
mation.23,29 Our findings suggest a novel mechanism, namely an
inducible defect in local endogenous fibrinolytic activity, favouring
local thrombus formation in the pathophysiology of microvascular
obstruction and re-infarction. In support of this hypothesis, strep-
tokinase reduces myocardial congestion and improves microvascu-
lar perfusion in a canine model of IR injury30 and acutely improves
indices of coronary microvascular perfusion when administered
immediately following primary percutaneous coronary interven-
tion in patients with ST-segment elevation myocardial infarction.31
Direct assessment of coronary endothelial function in vivo in man
necessitates complex invasive studies with obvious limitations. The
accessibility of the forearm vascular bed makes it an attractive
model by which to assess vascular function in vivo. Although less
susceptible to atherosclerosis and thrombosis, consistent findings
between the peripheral2,6,32 and coronary circulations8,33,34
provide support for the forearm model as a surrogate for the cor-
onary circulation.35
Limitations
We employed a robust, randomized, cross-over study design.
Although study investigators were blinded to the intervention per-
formed at each visit (IR injury, ischaemic preconditioning, or sham),
for obvious reasons it was not possible to ensure blinding of the
study subjects. Forearm venous sampling during local infusion of
agonists is a well established technique in the assessment of
endogenous t-PA release.4,6,7,36 To minimize the potential for
regional variation in venous effluent, venous sampling is always per-
formed from a large vein located in the antecubital fossa.
Intravascular thrombus formation is dependent on a number of
factors, including the endothelial function, the coagulation cascade,
and platelets.5 We have previously demonstrated that IR injury
increases markers of platelet activation and that remote ischaemic
preconditioning protects against this platelet activation.37 The
current study was designed to examine the effects of IR injury
Figure 4 Effect of ischaemia–reperfusion injury alone and ischaemia–reperfusion injury preceded by local or remote ischaemic precondition-
ing on substance P-induced net release of tissue plasminogen activator antigen and activity (Protocol 2). IR indicates ischaemia–reperfusion; IPC,
local ischaemic preconditioning; RIPC, remote ischaemic preconditioning; and t-PA, tissue-plasminogen activator. Data analysed using two-way
ANOVA with repeated measures.
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and ischaemic preconditioning on a specific aspect of endothelial
function, t-PA release, intimately involved in thrombus formation.
In addition to t-PA antigen, we assessed enzymatic activity using
a standard immunological technique. We acknowledge that this
model may be relatively simplistic in the context of the complex
in vivo response to thrombus formation. There are, however,
obvious methodological difficulties in directly assessing the effect
of endogenous t-PA release on arterial thrombosis in vivo in man.
Further work is required to examine the effects of ischaemic pre-
conditioning and IR injury on the coagulation cascade and markers
of inflammation in vivo in man.
In summary, we have demonstrated that substance P-induced
endothelium-dependent vasodilatation and t-PA release are
impaired following IR injury in the human forearm. In contrast to
acetylcholine, neither local nor remote ischaemic preconditioning
protected against the impairment of substance P-mediated vaso-
motor and fibrinolytic function induced by IR injury. Our findings
support an inducible defect in endogenous fibrinolysis as a novel
mechanism in the pathophysiology of IR injury in man.
Supplementary material
Supplementary material is available at European Heart Journal
online.
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